Zentalis Q1 cash $489M; multiple azenosertib data readouts H2 2024–2025

Zentalis Pharmaceuticals, Inc.

2024-Q1 EPS reported $0.14 revenue$40,560,000

Cash, equivalents & marketable securities $489.0M (incl $56.7M Immunome stock); projected runway to mid-2026.
R&D expense $49.6M (up $1M YoY); G&A $15.7M (down $0.7M). Quarterly net loss not disclosed.
Key milestones: Phase 1 osteosarcoma data at 2024 ASCO; DENALI (PROC) topline H1 2025; TETON (USC) topline H2 2025.
Interim CFO Cam Gallagher appointed April 5, 2024; search for permanent CFO underway.
Azenosertib development on track with partnerships (GSK, Pfizer); registration-enabling trial in PSOC planned for 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.96

Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024, Zentalis Pharmaceuticals, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024 and commented on certain business updates.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-24-000106

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.